TY - JOUR
T1 - Mutation analysis of the RET receptor tyrosine kinase in hirschsprung disease
AU - Angrist, Misha
AU - Bolk, Stacey
AU - Thiel, Bonnie
AU - Puffenberger, Erik G.
AU - Hofstra, Robert M.
AU - Buys, Charles H.C.M.
AU - Cass, Daniel T.
AU - Chakravarti, Aravinda
N1 - Funding Information:
We are extremely grateful to all of the families who have participated in our studies, particularly the membership of the American Pseudo-obstruction and Hirschsprung's Disease Society, Inc. (APHS) and patients ascertained through members of the American Pediatric Surgical Association (APSA), without whom this study would not have been possible. We also thank Dr J.Timothy Boyle (Rainbow Babies and Children's Hospital, Cleveland, OH) for providing clinical advice, and David Winkler for expert technical assistance. We are grateful to Dr Giovanni Romeo (Instituto G.Gaslini, Genova, Italy) for thoughtful discussion and to two anonymous reviewers for helpful comments and suggestions. This work was supported by NIH grant HD28088 to A.C. and by grant GUKC91-I4 from the Dutch Cancer Society to C.H.C.M.B.
PY - 1995/5
Y1 - 1995/5
N2 - Hirschsprung disease (HSCR), or congenital agangiionic megacolon, is the most common cause of congenital bowel obstruction with an incidence of 1 in 5000 live births. Recently, linkage of an incompletely penetrant, dominant form of HSCR was reported, foilowed by identification of mutations in the RET receptor tyrosine kinase. To determine the frequency of RET mutations in HSCR and correlate genotype with phenotype, we have screened for mutations among 80 HSCR probands representing a wide range of phenotypes and family structures. Polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) analysis of RET's 20 exons for mutations among probands revealed eight putative mutations (10%). Sequence changes, which included missense, frameshift and complex mutations, were detected in both familial and isolated cases, among patients with both long-and short-segment HSCR and in three kindreds with other phenotypes (maternal deafness, talipes and mairotation of the gut, respectively). Two mutations (C609Y and C620R) we identified have previously been associated with multiple endocrine neoplasla type 2A (MEN2A), medullary thyroid carcinoma (MTC) and, on rare occasions, HSCR. Thus, while HSCR family members may be at risk for developing neuroendocrine tumors, it follows that identical mutations in RET may be able to participate in the pathogenesis of distinct phenotypes. Our data suggest that: (i) the overall frequency of RET mutations in HSCR patients is low and therefore, other genetic and/or environmental determinants contribute to the majority of HSCR susceptibility, and (ii) at present, there is no obvious relationship between RET genotype and HSCR phenotype.
AB - Hirschsprung disease (HSCR), or congenital agangiionic megacolon, is the most common cause of congenital bowel obstruction with an incidence of 1 in 5000 live births. Recently, linkage of an incompletely penetrant, dominant form of HSCR was reported, foilowed by identification of mutations in the RET receptor tyrosine kinase. To determine the frequency of RET mutations in HSCR and correlate genotype with phenotype, we have screened for mutations among 80 HSCR probands representing a wide range of phenotypes and family structures. Polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) analysis of RET's 20 exons for mutations among probands revealed eight putative mutations (10%). Sequence changes, which included missense, frameshift and complex mutations, were detected in both familial and isolated cases, among patients with both long-and short-segment HSCR and in three kindreds with other phenotypes (maternal deafness, talipes and mairotation of the gut, respectively). Two mutations (C609Y and C620R) we identified have previously been associated with multiple endocrine neoplasla type 2A (MEN2A), medullary thyroid carcinoma (MTC) and, on rare occasions, HSCR. Thus, while HSCR family members may be at risk for developing neuroendocrine tumors, it follows that identical mutations in RET may be able to participate in the pathogenesis of distinct phenotypes. Our data suggest that: (i) the overall frequency of RET mutations in HSCR patients is low and therefore, other genetic and/or environmental determinants contribute to the majority of HSCR susceptibility, and (ii) at present, there is no obvious relationship between RET genotype and HSCR phenotype.
UR - http://www.scopus.com/inward/record.url?scp=0029069528&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029069528&partnerID=8YFLogxK
U2 - 10.1093/hmg/4.5.821
DO - 10.1093/hmg/4.5.821
M3 - Article
C2 - 7633441
AN - SCOPUS:0029069528
SN - 0964-6906
VL - 4
SP - 821
EP - 830
JO - Human molecular genetics
JF - Human molecular genetics
IS - 5
ER -